IRLAB Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kristina Torfgard

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	11.8yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

CEO

Kristina Torfgard (61 yo)

less than a year

Tenure

Dr. Kristina Torfgard, Ph.D. is Chief Executive Officer of IRLAB Therapeutics AB (publ) from August 1, 2024. Dr. Torfgard served as Vice President & Global Project Head at Albireo AB. Dr. Torfgard served a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristina Torfgard	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Viktor Siewertz	Chief Financial Officer	7.8yrs	geen gegevens	0.46% SEK 3.1m
Clas Sonesson	Chief Scientific Officer	11.8yrs	geen gegevens	1.46% SEK 9.9m
Peder Svensson	Chief Information Officer and Director of Computational Chemistry & Biology	11.8yrs	geen gegevens	0.50% SEK 3.4m
Tove Bergenholt	Global IR & Communications	no data	geen gegevens	geen gegevens
Cecilia Stenberg	Head of Finance & Human Resource and Director of Accounting & Human Resources	11.8yrs	geen gegevens	0.70% SEK 4.8m
Nicholas Waters	Executive VP and Head of R&D	no data	SEK 1.70m	1.44% SEK 9.8m
Joakim Tedroff	Chief Medical Officer	11.8yrs	SEK 5.00k	1.22% SEK 8.3m

11.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IRLAB A is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rein Piir	Independent Director	8.8yrs	SEK 256.25k	0.081% SEK 548.9k
Carola Lemne	Independent Chairman of the Board	6.8yrs	SEK 400.00k	0.027% SEK 183.4k
Christer Nordstedt	Director	1.4yrs	SEK 147.50k	geen gegevens
Veronica Wallin	Independent Director	1.4yrs	SEK 160.00k	geen gegevens
Gunnar Olsson	Director	7.8yrs	SEK 3.10m	0.012% SEK 78.6k
Catharina Wallich	Independent Director	2.5yrs	SEK 264.17k	0.015% SEK 104.8k
Daniel Johnsson	Director	1.4yrs	SEK 175.00k	8.71% SEK 59.2m

2.5yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IRLAB A wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

IRLAB Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

IRLAB Therapeutics AB (publ), Annual General Meeting, May 21, 2025

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

Director recently bought kr260k worth of stock

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

Recent updates

IRLAB Therapeutics AB (publ), Annual General Meeting, May 21, 2025

New minor risk - Profitability

IRLAB Therapeutics AB (publ) to Report Q2, 2025 Results on Jul 09, 2025

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics AB Receives Milestone Payment of USD 2.5 Million in Conjunction with First Dosing in A Phase I Study with IRL757 in Healthy Adults

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

New minor risk - Profitability

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Independent Vice Chairman of the Board recently bought kr330k worth of stock

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2021 Results on Apr 08, 2022

Independent Chairman recently bought kr74k worth of stock

Irlab Obtains Regulatory Approval to Conduct Phase IIb Study with Pirepemat

Independent Director recently bought kr112k worth of stock

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow